Compare Tango Therapeutics Inc. (TNGX) vs YPF Sociedad Anonima American Depositary Shares (YPF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs YPF Sociedad Anonima American Depositary Shares — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while YPF Sociedad Anonima American Depositary Shares trades at $52.6 (market cap $20.49B). The key difference: YPF Sociedad Anonima American Depositary Shares is far larger — about 5.5× Tango Therapeutics Inc.'s market cap, and YPF Sociedad Anonima American Depositary Shares is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and YPF Sociedad Anonima American Depositary Shares for 6 Days on average.
| TNGX | YPF | |
|---|---|---|
Market Cap | $3.74B | $20.49B |
Volume | 3,438,781 | 811,824 |
Sector | Health | Energy |
52-Week High | $32.90 | $57.61 |
52-Week Low | $7.50 | $24.71 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.76B | $28.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
YPF trades at $51.79, down 0.35% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with Q2 2026 earnings beating estimates and strong revenue growth from $18.3B in 2025 to $20.6B projected for 2026. Recent developments include a $24B LNG project gaining U.S. financing support and record quarterly cash flow generation.
The outlook remains positive with analyst consensus at Buy (46.7%) and a $56.67 price target representing 9.4% upside. Key risks include political uncertainty in Argentina and execution challenges for major capital projects. The stock offers value with attractive EV/EBITDA of 3.91x but faces margin pressure from high tax burdens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About YPF Sociedad Anonima American Depositary Shares
YPF is an integrated energy company in Argentina. Its operations span oil and gas exploration and production, transportation, refining, and the marketing of petroleum products.
Read more on YPF →
